Elements Compounding Pharmacy vs. PCAB-Accredited Alternatives: The 2026 Quality Evaluation Framework Every Patient Needs
Introduction: Why Your Compounding Pharmacy Choice Matters More Than Ever in 2026
For patients searching for Elements Compounding Pharmacy in Mesa, Arizona, or evaluating a comparable local compounder, the timing could not be more consequential. The stakes for choosing a compounding pharmacy have never been higher.
Consider the numbers. The U.S. compounding pharmacy market was valued at roughly $6.98 billion in 2025 and is projected to reach $12.79 billion by 2035, growing at a compound annual rate of 6.24%. Yet despite this explosive growth, fewer than 1% of U.S. pharmacies hold PCAB (Pharmacy Compounding Accreditation Board) accreditation, the industry’s gold-standard quality credential.
That gap matters. An estimated 30 to 40 million compounded prescriptions are filled every year across roughly 7,500 pharmacies that offer compounding services. Those pharmacies, however, do not all operate at the same quality tier. Some invest heavily in accreditation, sterile capability, and independent testing. Others do not.
Rather than serve as another directory listing, this article delivers something more useful: a five-criteria quality evaluation framework that any patient or provider can apply to any compounding pharmacy, including Elements, to make a genuinely informed decision.
The 2026 regulatory context makes this framework essential. The foundational USP standards achieved final enforceable status on November 1, 2023. FDA enforcement has escalated sharply, with roughly 100 cease-and-desist letters issued in September 2025 alone. State-level requirements are tightening across the country, and credential verification is no longer optional.
This is a tool for empowerment, not an attack on any specific pharmacy.
What Is Elements Compounding Pharmacy? A Baseline Profile
Elements Compounding Pharmacy is a non-sterile compounding pharmacy located at 2110 E Baseline Rd, Suite 5, Mesa, AZ 85204. It operates Monday through Friday from 10:00 AM to 6:00 PM and can be reached at (480) 625-4750.
The pharmacy advertises a broad menu of non-sterile services, including hormone replacement therapy, thyroid medications, pediatric medications, pain management, dermatology, and veterinary compounding. One of its headline selling points is speed: Elements advertises a turnaround of less than 24 hours on most compounded prescriptions.
From a regulatory standpoint, Elements is a 503A non-sterile compounding pharmacy. Its materials are sourced from FDA-registered suppliers, though it is important to understand that the FDA has not evaluated the safety and efficacy of any specific compounded preparations. This is standard for all 503A compounding pharmacies, but patients should be aware of it.
One point deserves careful attention: brand confusion. There are multiple distinct pharmacy entities using the “Elements” name. One is in Mesa, Arizona (elementspharmacy.com), and another operates in Studio City, California (elementspharmacyrx.com). These are separate businesses. Patients should verify they are contacting the correct location before submitting any prescription or personal information.
To be fair, Elements offers genuine benefits. Local accessibility, a broad non-sterile compounding menu, and fast turnaround are real advantages for patients in the Mesa area with straightforward needs. Those attributes matter, but they represent only part of the quality picture, which is precisely why a structured evaluation framework is essential.
The 2026 Quality Evaluation Framework: Five Criteria That Separate Good from Great
The framework below is a practical, credential-first tool for evaluating any compounding pharmacy, built for 2026, a year when the regulatory environment sits at a clear inflection point.
Consider what has changed. California’s new regulation, effective October 1, 2025, requires pharmacists to verify a “clinically significant difference” for compounded drugs. Kentucky began active enforcement of revised USP standards on January 1, 2026. The proposed SAFE Drugs Act (H.R. 6509) is reshaping what baseline compliance looks like at the federal level. The definition of a quality compounder is being rewritten in real time.
The strength of these five criteria is that they are objective, verifiable, and publicly checkable. Patients and providers do not need to take a pharmacy’s word for anything.
A note on why verification is not optional: a 2020 systematic review published in the Journal of Medical Toxicology identified 63 compounding errors from 2,155 reports, including 27 contamination errors that harmed 1,119 patients. Quality failures carry real consequences.
Each criterion below is framed as a direct question any patient or provider can ask.
Criterion 1: PCAB Accreditation, the Industry’s Gold Standard
Achieving it is demanding. PCAB accreditation requires alignment to USP standards <795>, <797>, and <800>, a rigorous on-site evaluation, and ongoing compliance monitoring. It is a voluntary credential that goes well beyond minimum state licensing requirements.
That difficulty is why fewer than 1% of U.S. pharmacies hold it, making PCAB accreditation a powerful differentiator. The trend is also moving toward accreditation as a baseline expectation: Washington and Ohio now require verifiable PCAB accreditation for nonresident pharmacy licensure.
The question to ask: “Are you currently PCAB-accredited, and can you provide your accreditation number for independent verification?”
Applied to Elements: Elements Compounding Pharmacy’s website does not prominently feature PCAB accreditation. Patients should verify this directly before proceeding.
Applied to Nationwide Compounding Rx®: PCAB-accredited, providing independent, third-party-verified quality assurance that patients and providers can confirm.
Criterion 2: USP <800> Compliance, Protecting Patients and Staff from Hazardous Drug Exposure
Three foundational USP standards anchor compounding quality. USP <795> governs non-sterile compounding, USP <797> governs sterile compounding, and USP <800> governs hazardous drug handling. All three achieved final enforceable status on November 1, 2023.
USP <800> deserves special focus. It establishes requirements for receiving, storing, compounding, and dispensing hazardous drugs to protect healthcare workers, patients, and the environment.
This matters for patients because it ensures that hormone therapies, chemotherapy-adjacent compounds, and other hazardous drug categories are handled with appropriate containment, reducing contamination risk. Compliance also requires significant facility investment: specialized ventilation, containment primary engineering controls (C-PECs), and staff training. Not all pharmacies can or do meet this standard.
The question to ask: “Is your facility USP <800> compliant, and has this been verified by an accrediting body or state inspection?”
Applied to Elements: As a non-sterile pharmacy, USP <800> applicability depends on whether it handles hazardous drugs. Patients should ask directly.
Applied to Nationwide Compounding Rx®: Explicitly USP <800> compliant, with PCAB accreditation providing third-party verification of that compliance.
Criterion 3: Sterile Compounding Capability, When Non-Sterile Is Not Enough
Non-sterile preparations include capsules, topicals, troches, and oral liquids. Sterile preparations include injectables, ophthalmic solutions, and IV admixtures, all of which require a cleanroom environment meeting ISO classification standards under USP <797>.
This distinction has real clinical consequences. Many therapeutic categories, including certain pain management injections, hormone pellets, and peptide therapies, require sterile preparations. A non-sterile-only pharmacy cannot safely provide these.
Sterile compounding also demands substantially greater facility investment, environmental monitoring, and staff credentialing. The stakes are illustrated by the FDA’s recent GLP-1 enforcement wave: roughly 100 cease-and-desist letters in September 2025 and 30 additional warning letters in March 2026, with many violations involving sterile preparation quality failures.
The question to ask: “Do you compound sterile preparations, and are you USP <797> compliant with documented environmental monitoring?”
Applied to Elements: Elements is explicitly a non-sterile compounding pharmacy. Patients needing sterile preparations must seek an alternative.
Applied to Nationwide Compounding Rx®: Capable of both sterile and non-sterile formulations, with USP <797> compliance supported by PCAB accreditation.
Criterion 4: Multi-State Shipping Infrastructure, Access Beyond Your ZIP Code
503A pharmacies are state-regulated, and shipping across state lines requires active licensure in each destination state. This is not automatic; it requires ongoing compliance investment.
The relevance of this criterion is increasingly obvious. Provider-patient relationships now routinely span state lines through telehealth, relocation, and specialist referrals. A pharmacy limited to one metro area cannot serve patients who move or travel.
Federal scrutiny is intensifying as well. The proposed SAFE Drugs Act (H.R. 6509), introduced in December 2025, would require pharmacies shipping more than 20 out-of-state prescriptions to report to the FDA, making proper multi-state licensure even more important.
The question to ask: “In which states are you currently licensed to ship compounded medications, and does that include both sterile and non-sterile preparations?”
Applied to Elements: Both Elements brand pharmacies (Mesa, AZ and Studio City, CA) are geographically limited local pharmacies with no evidence of multi-state shipping infrastructure.
Applied to Nationwide Compounding Rx®: Operates a tiered multi-state shipping footprint with three license tiers (fully licensed states; non-sterile only with sterile pending; and pending or unlicensed states), providing transparent, verifiable multi-state access.
Criterion 5: Independent Third-Party Testing, Verifying What the Label Claims
Independent third-party testing means laboratory analysis of finished preparations to verify potency, sterility, endotoxin levels, and the absence of contaminants, conducted by a lab with no financial relationship to the compounding pharmacy.
This is distinct from in-house quality control. Internal checks are necessary but not sufficient. Independent testing removes the conflict of interest inherent in self-verification.
The 2020 Journal of Medical Toxicology review is instructive here: 27 contamination errors harmed 1,119 patients, and many could have been caught by rigorous independent testing protocols.
Sourcing matters as well. High-quality compounding requires active pharmaceutical ingredients (APIs) sourced exclusively from FDA-inspected and cleared vendors. This is a live regulatory issue: Florida and Indiana introduced legislation in 2026 tightening API sourcing documentation requirements.
The question to ask: “Do you conduct independent third-party testing on finished preparations, and can you provide certificates of analysis?”
Applied to Elements: The Elements website does not prominently feature independent third-party testing or API sourcing verification. Patients should request this documentation directly.
Applied to Nationwide Compounding Rx®: Conducts independent third-party testing and sources high-grade chemicals exclusively from FDA-inspected and cleared vendors, with PCAB accreditation providing structural oversight of these practices.
Applying the Framework: A Side-by-Side Comparison
The table below applies all five criteria to a typical non-accredited local compounder (represented by the publicly available Elements profile) and to Nationwide Compounding Rx®.
| Criterion | Elements (Local Compounder) | Nationwide Compounding Rx® |
|---|---|---|
| PCAB Accreditation | Not prominently featured / unverified | PCAB-accredited (verified) |
| USP <800> Compliance | Status unconfirmed publicly | USP <800> compliant (verified) |
| Sterile Compounding | Non-sterile only (explicitly stated) | Sterile and non-sterile capable |
| Multi-State Shipping | Local Mesa, AZ footprint only | Multi-state footprint with tiered licensing |
| Third-Party Testing | Not prominently featured | Independent testing with FDA-cleared API sourcing |
This comparison is not an attack on Elements. It simply illustrates what the framework reveals when applied objectively.
Elements may serve patients in Mesa, Arizona well for local, non-sterile needs. Patients with more complex requirements, or those outside the Phoenix metro area, face meaningful gaps. Nationwide Compounding Rx® was built to address exactly those gaps: PCAB-accredited quality, sterile capability, and nationwide reach from its Scottsdale, Arizona facility.
Why 2026 Is the Year to Demand More from Your Compounding Pharmacy
The regulatory landscape has reached a genuine inflection point. USP <795>, <797>, and <800> are now fully enforceable. State-level requirements are tightening in California, Kentucky, Florida, and Indiana. FDA enforcement has hit an unprecedented level.
The GLP-1 enforcement wave is a clear patient-protection signal: more than 100 cease-and-desist letters in September 2025, 30 warning letters in March 2026, and another 25 in June 2026, all targeting misleading claims about compounded medications.
For patients, the implications are significant. The gap between accredited and non-accredited pharmacies is widening as requirements increase. Meanwhile, the market’s projected growth from $6.98 billion in 2025 to $12.79 billion by 2035 means more pharmacies are entering the space, making credential verification even more important for distinguishing true quality operators.
Consider where risk concentrates most. Hormone replacement therapy is the fastest-growing therapeutic segment, projected to grow at 7.86% CAGR from 2026 to 2031. That is precisely the specialty where quality failures carry the highest patient risk.
In this environment, PCAB accreditation, USP compliance, sterile capability, multi-state shipping, and independent third-party testing are not luxury features. They are baseline quality expectations.
How Nationwide Compounding Rx® Meets Every Criterion in the Framework
Applying the framework to Nationwide Compounding Rx® yields a consistent result across all five criteria:
- PCAB Accreditation: Confirmed, providing the industry’s gold-standard quality verification.
- USP <800> Compliance: Confirmed, ensuring hazardous drug handling meets the highest enforceable standard.
- Sterile Compounding Capability: Both sterile and non-sterile formulations available, covering the full spectrum of patient needs including injectables and ophthalmic preparations.
- Multi-State Shipping: A multi-state footprint with a transparent three-tier licensing map, so patients can verify their state’s service level before submitting a prescription.
- Independent Third-Party Testing: Conducted on finished preparations, with APIs sourced exclusively from FDA-inspected and cleared vendors.
Additional differentiators reinforce the picture: 40-plus years of combined team experience; a one to two business day turnaround with same-day pickup on select medications; a broad therapeutic menu spanning BHRT, GLP-1 and peptide support, pain management, dermatology, pediatrics, and sports medicine; allergen-free formulation capabilities; and secure provider and patient portals.
Location and contact: 14000 N. Hayden Rd., Suite 104, Scottsdale, AZ 85260; (480) 499-8379; Monday through Friday, 7:00 AM to 3:30 PM.
The pharmacy operates on a structured provider partnership model: Connect → Collaborate → Create → Care, designed for seamless integration with prescribers and healthcare teams.
Conclusion: Use the Framework, Make the Right Choice
The five-criteria framework is straightforward: PCAB accreditation, USP <800> compliance, sterile compounding capability, multi-state shipping, and independent third-party testing. Any patient or provider can, and should, apply these criteria to any compounding pharmacy before making a decision.
Local pharmacies may meet some needs well, but the framework objectively reveals where gaps exist. In the 2026 regulatory environment, choosing a PCAB-accredited, fully compliant pharmacy is the most reliable way to protect patient safety and ensure medication quality. Nationwide Compounding Rx® meets all five criteria, not by self-declaration, but through verifiable, third-party-confirmed credentials.
Patients and providers who use this framework will always know exactly what they are getting and exactly what questions to ask.
Ready to Work With a PCAB-Accredited Compounding Pharmacy? Contact Nationwide Compounding Rx® Today
For patients: Contact Nationwide Compounding Rx® to discuss specific medication needs. Call (480) 499-8379, Monday through Friday, 7:00 AM to 3:30 PM, or connect through the secure patient portal at nationwidecompounding.com.
For providers: Connect through the secure provider portal to submit prescriptions, manage orders, and partner with the pharmacy team using the Connect → Collaborate → Create → Care framework.
Serving patients across multiple licensed states, the pharmacy makes it easy to check the state licensing map and confirm availability before beginning the process.
A quick credential summary: PCAB-accredited, USP <800> compliant, sterile and non-sterile capable, with independent third-party testing. All five framework criteria met.
Patients and providers are welcome to independently verify PCAB accreditation status before reaching out, a reflection of the pharmacy’s confidence in its credentials.
Personalized, quality-verified medications built around individual patient needs: that is the standard every patient deserves in 2026.
Related Posts
The primary Accredo Specialty Pharmacy phone number for refills and orders is 800-803-2523 — but that's just the start. This guide lists every Accredo contact line organized by purpose, and explains your options when calls alone don't solve the problem.
When the medicine cabinet is full of half-used tubes and nothing seems to work, a custom topical cream for skin conditions may be the answer. Unlike mass-produced treatments, compounded creams are formulated for your unique needs. Discover why commercial options fall short and how personalized compounding changes the outcome.
Commercial muscle recovery products aren't built for serious athletes—and 2026 research confirms it. This evidence-based guide explores how compounding pharmacy delivers custom formulations proven to outperform off-the-shelf options. From anti-doping compliance to the female athlete medication gap, get the clinical insights that matter.
Elite personalized medicine is no longer a luxury—it is the clinical standard in 2026. PCAB-accredited compounding pharmacies translate genomic insights and lab data into patient-specific formulations across BHRT, men's health, GLP-1 support, and beyond. Learn why accreditation defines precision care today.
